1. Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. (24th March 2022) Authors: Coutre, Steven E; Barnett, Christopher; Osiyemi, Olayemi; Hoda, Daanish; Ramgopal, Moti; Fort, Alexander C; Qaqish, Roula; Hu, Yiran; Ninomoto, Joi; Alami, Negar N; Styles, Lori; Treon, Steven P Journal: Open forum infectious diseases Issue: Volume 9:Number 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Issue 10 (October 2016) Authors: O'Brien, Susan; Jones, Jeffrey A; Coutre, Steven E; Mato, Anthony R; Hillmen, Peter; Tam, Constantine; Österborg, Anders; Siddiqi, Tanya; Thirman, Michael J; Furman, Richard R; Ilhan, Osman; Keating, Michael J; Call, Timothy G; Brown, Jennifer R; Stevens-Brogan, Michelle; Li, Yunfeng; Clow, Fong;... Journal: Lancet oncology Issue: Volume 17:Issue 10(2016:Oct.) Page Start: 1409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. (23rd March 2018) Authors: Yeung, Cecilia CS; Hockenbery, David M; Westerhoff, Maria; Coutre, Steven E; Sedlak, Ruth H; Dubowy, Ronald L; Munugalavadla, Veerendra; Taylor, Kerry; Bosch, Francesc Journal: Future oncology Issue: Volume 14:Number 22(2018) Page Start: 2265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗